Kornimate/medical-research-clean huggingface dataset:
circulating tumor cells in non-small cell lung carcinoma

Conditions: Primary Lung Cancer

Summary: the purpose of this study is to establish the circulating tumor cell (ctc) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. this is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at yale university/yale-new haven hospital, university of california san diego/moores cancer center, billings clinic cancer center.


Eligibility criteria:
inclusion criteria: * suspected lung cancer * planned to undergo tissue biopsy. tissue biopsy does not need to be limited to an intrathoracic structures. biopsies of the supraclavicular lymph nodes are allowed * age \>18 exclusion criteria: * patients with history of a separate (not a primary lung cancer) malignancy within past two years. * recent history (past two weeks) of trauma (including diagnostic surgery, biopsy, etc) * prior lung cancer treatment chemotherapy, radiation, surgery, etc. in past two years. * inability to provide informed consent. * hgb less than 8.
transnasal sphenopalatine ganglia block for management of chronic migraines in pediatric patients

Conditions: Migraine in Children; Pain, Neuropathic

Summary: single-center, open-label, pre-post treatment pilot study to evaluate the safety and effectiveness of sphenopalatine ganglia blocks for the treatment of chronic migraine in the pediatric population. 50 children with a diagnosis of chronic migraines will undergo a series of three transnasal sphenopalatine ganglia blocks to measure their effect on headache frequency, headache intensity, headache duration, and use of headache medication.


Eligibility criteria:
inclusion criteria: children ages 8 to 17 years old meet the criteria for chronic migraines have remained stable on their current headache medication for a minimum of 4 weeks. able to provide informed consent from parent or legal guardian able to provide assent if subject is a minor of appropriate age exclusion criteria: allergy to local anesthetic developmental delay (e.g. non-verbal) inability to use numeric pain scale inability to perform or tolerate transnasal procedure substance abuse disorders known pregnancy
role of interleukin-6 in exercise

Conditions: Diabetes Mellitus, Type 2; Obesity

Summary: the purpose of the study is to understand the role of interleukin-6 during physical activity in patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * obesity group: bmi 30-40 kg/m2, fasting plasma glucose \<6.4 mmol/l. * diabetes group: type 2 diabetes according to american diabetes association criteria exclusion criteria: * anti-diabetic drug other than metformin * diabetes duration of more than 5 years * inflammatory diseases * current infection * liver disease (transaminases \>2x upper normal range) * kidney disease (creatinine \>1.5 mg/dl for men and 1.4 mg/dl for women) * pregnancy or breast-feeding, women of child bearing potential not using an acceptable form of contraception * immunosuppressive disease * corticosteroid use * regular non-steroidal antinflammatory drug usage * history of carcinoma * history of tuberculosis * anemia, bleeding disorders * obstructive pulmonary disease.
effectiveness of two water-based potassium oxalate desensitizers on dental hypersensitivity

Conditions: Dentin Sensitivity

Summary: this study will compare the safety and effectiveness of two water-based potassium oxalate desensitizers on existing dentinal hypersensitivity.


Eligibility criteria:
inclusion criteria: * provide written informed consent to participate in the study * be at least 18 years of age * be in good general health, as determined by the investigator/designee based on review of the health history/update for participation in the study * agree to refrain from participating in any other oral/dental product studies for the duration of the study * agree to refrain from receiving any elective dentistry (including dental prophylaxis) for the duration of the study * agree to refrain from using any oral hygiene products other than the assigned study products for the duration of the study * agree to comply with study/product usage instructions; and * have at least one tooth with gingival recession and hypersensitivity evidenced by a score of ≥ 1 on the cold air sensitivity schiff scale during screening exclusion criteria: * gross oral neglect or urgent dental treatment needs * severe periodontal disease and/or generalized mobility * active treatment for periodontitis * any disease or condition that could be expected to interfere with examination procedures or safe completion of the study * self-reported pregnancy or nursing

Keywords: sensitivity
treatment of fragile-x associated tremor/ataxia syndrome (fxtas) with allopregnanolone

Conditions: Fragile X-associated Tremor/Ataxia Syndrome

Summary: the purpose of this study is to examine the safety and efficacy of allopregnanolone as a possible treatment for symptoms of fragile x-associated tremor/ataxia syndrome (fxtas).

this study includes a screening visit with several assessments, followed by an open-label medication trial of allopregnanolone for 12 weeks and an end-point evaluation to assess for changes. assessments include blood draws for genetic and safety laboratory testing, neurological and physical exam and medical history, cognitive testing, and motor testing. study record was updated in october 2018 to include adverse events and outcome measure reporting. study record was updated in november 2018 in response to requests to (1) specify time frame of reported outcome measures, (2) clarify that the rass was a safety monitoring tool, not a prespecified outcome measure, and as such will not be reported as an outcome measure, and (3) upload a version of the study protocol and statistical analysis plan with the required title page and statistical analysis plan information.

Eligibility criteria:
inclusion criteria * fragile x premutation carrier status (55 to 200 cgg repeats in fmr1), * diagnosis of fxtas including an intention tremor and/or ataxia and/or deficits on the bds-2 demonstrating executive function deficits. exclusion criteria * other genetic problems in addition to the premutation * a history of significant brain trauma * significant substance abuse * inability to follow the protocol * liver or kidney disease * heart failure * active cancer * other serious systemic disease * current use of phenytoin
aspergillus pcr early detection in high risk oncohematological patients

Conditions: Infections

Summary: advance therapy aspergillosis invasive by pcr detection

advance therapy aspergillosis invasive in patients high risk oncohematological pcr using for early detection of aspergillus

Eligibility criteria:
inclusion criteria: * signature of informed consent to participate in the study. * adult patients (\> 18 years), diagnosed with acute myelogenous leukemia or myelodysplastic syndrome with chemotherapy (ct) intensive, or admitted to undergo allogeneic hematopoietic progenitor cells, or transplantation with graft versus host disease. * the patient should be included in this protocol from the start of their chemotherapy or conditioning therapy as reflected in another section. exclusion criteria: * employment of antifungal prophylaxis (30 days prior to inclusion) with triazole / polyene with activity against aspergillus (itraconazole, voriconazole, posaconazole, amphotericin b inhalation). * use of other systemic antifungal activity against aspergillus (amphotericin, terbinafine, flucytosine, echinocandins, etc.). therefore it will fluconazole prophylaxis exclusively. * background of ifi proven / probable prior * probable ifi / tested at the time of inclusion in the study. * exclusion will cause a lack of compliance with the inclusion criteria. * patients who have a lack of follow biweekly with galactomannan or pcr. have a bacterial infection not properly treated and controlled before starting empirical antifungal treatment (according to the definition given above). and finally they have a neutropenia of short duration that it creates a significant risk of ifi. this information will not be known logically to include the patient in the study.

Keywords: high risk aspergillosis infection patients
nurse-performed lung ultrasound versus chest radiography for detection of pneumothorax.

Conditions: Pneumothorax; Cardiac Surgery

Summary: this is a prospective, single-center, observational, cross-sectional cohort study, comparing nurse-performed bedside lung ultrasound to standard portable cxr, for the detection of pneumothorax in the cardiac surgery patient population, following chest tube removal. this study aims to be conducted at an academic, tertiary adult center cardio-vascular intensive care unit (cvicu at tgh).

to avoid the accumulation of blood and fluids in the mediastinum or pleural cavities after cardiac surgery, mediastinal and pleural drains are routinely used. the rate of pneumothorax following chest drain removal is approximately 1.5-13%, resulting in increased patient morbidity and hospital stay. the standard method for the determination of pneumothorax (pnx) in most institutions is to obtain a chest radiography (cxr) following chest tube removal, but the reliability of the supine anteroposterior chest radiography is not utter, with up to 30% of pneumothoraxes misdiagnosis. the delay of ordering, performing and interpreting a cxr post mediastinal tube removal, results in potential delay in patients transfers, with an estimated cost savings of omitting an additional chest radiography, of approximately $10 000 per year. lung ultrasound (lus) is recommended for detection of pneumothorax as per evidence-based guidelines and expert consensus. lung ultrasound is a safe technique due to minimal radiation, with the potential for immediate results when compared with the standard cxr. lus has high accuracy for pnx detection, with better pooled sensitivities (78.6%) when compared to cxr (39.8%) and equal specificity (98.4 vs 99.3%). in intensive care units, those results have been reproducible, with lus having greater sensitivity than cxr for pnx diagnosis (0.87 vs 0.46) and equal specificity, 0.99 vs 1.00. lus is more accurate and faster than chest radiography.

Eligibility criteria:
inclusion criteria: * patients older than 18 years in the cardiovascular intensive care unit post cardiac surgery, with a chest tube removed within the past 2 hours. exclusion criteria: * patients who were mechanically ventilated or with subcutaneous emphysema due to impaired pleural line visualization.

Keywords: chest tube removal
translating research: patient decision support/coaching

Conditions: Acute Coronary Syndrome

Summary: the purpose of the study was to test a telephone counseling intervention for patients after leaving the hospital for a heart attack to use medication, exercise, healthy eating and smoking cessation to prevent further heart attacks.

background: efficacy of brief individual telephone coaching for secondary prevention behavior has been shown. however, the independent contribution of personal counseling to system-level intervention is untested. we tested a multiple-risk factor brief counseling intervention in acute coronary syndrome (acs) following hospital-based quality improvement (qi) program. methods: patient-level randomized trial of hospital quality improvement (qi-only) versus quality improvement plus brief telephone coaching in the first three months post-hospitalization (qi-plus) for patients hospitalized for acs. data collection: medical record review, state vital records, and post-hospital surveys (baseline, 3 and 8 months post hospitalization). main outcomes: secondary prevention behaviors, physical functioning, and quality of life. results: qi-plus patients reported statistically significant independent improvements in physical activity (or = 1.62; p = .01) during the intervention, and were more likely to participate in formal cardiac rehabilitation (or = 2.51; p = .02). smoking cessation was not statistically different (or = 1.31; p = .68); functional status and quality of life were not different at 8 months. medication use was high in qi and qi-plus groups, and improved over prior cohorts in the same hospitals. conclusion: qi improved physician and patient adherence to guidelines and improved medical therapy in-hospital continued in the outpatient setting. brief telephone coaching was modestly effective in accomplishing short-term, but not long-term life-style behavior change. patient life-style behavior change appears to require sustained intervention. qi-based improvement in medication use improves survival and appears to be the most efficient route to improved outcomes for all patients.

Eligibility criteria:
inclusion criteria: 1. age of 21 years or older, 2. a documented serum troponin i level of greater than, or equal to the upper limits of normal in each hospital, and 3. a working diagnosis of acs in the medical record. exclusion criteria: 1. inability to speak english or to complete the enrollment interview, and 2. discharge to a non-home setting.

Keywords: quality improvement patient-centered care acute coronary syndrome telephone counseling
emotional reaction and self injury in patients with borderline personality disorder and healthy controls

Conditions: Borderline Personality Disorder; Emotions

Summary: the current study investigates the emotional response of patients with borderline personality disorder and healthy controls on stimuli associated with self-injury.


Eligibility criteria:
inclusion criteria: * patients that are able to use skills and have some therapy experiences. exclusion criteria: * severe psychiatric comorbidity e.g. psychosis, severe depression, suicidality
dosimetric analysis of vaginal cuff brachytherapy in endometrial carcinoma

Conditions: Endometrial Carcinoma; Cervix Cancer; Carcinoma of the Uterus

Summary: the purpose of this study is to investigate the effect of certain variables such as the fullness of the patients bladder and the position of the treatment applicator on the dose of radiation that other organs such as the bladder and the rectum receive during radiation treatment for endometrial carcinoma.

* this study is separated into 2 phases. in phase 1, patients will be asked to have their bladder full for the second planned insertion of the brachytherapy applicator and empty for the third insertion. for phase 2, the effect of cylinder angle on normal tissue dosimetry will be investigated. of the two bladder states assessed in phase 1 (empty or full), the one deemed to give the lower dose to the total amount of bladder tissue will be considered the standard and applied to all patients in phase 2. * in phase 1, to standardize bladder filling, patients will be asked to empty their bladder, then to drink 32 oz of water one and a half hours before the ct scan. the patient will undergo a treatment-planning scan after the brachytherapy cylinder is inserted and before brachytherapy treatment. * in phase 2, patients will be asked to fill or empty their bladder according to the results of phase 1. the vaginal cylinder will be placed horizontally for the second treatment. the cylinder will then be angled at a specific angle for the subsequent treatment. * a history and physical exam will be performed within 2 weeks of study entry, then at 14 days, 90 days, and 180 days following the completion of therapy.

Eligibility criteria:
inclusion criteria: * histologic documentation of carcinoma of the uterus, post-hysterectomy stages i-iva or vaginal cuff recurrence. or post-hysterectomy cervix cancer stages ia or ib or post hysterectomy vaginal cancer stage i. * ecog performance status of less than or equal to 2 * 18 years of age or older exclusion criteria: * distant metastases * inoperable disease

Keywords: dosimetric analysis vaginal cuff brachytherapy
health care utilisation among survivors of childhood acute lymphoblastic leukaemia

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Summary: improved understanding of the long-time healthcare utilisation of childhood cancer survivors is relevant as it can be seen as a proxy for the population's morbidity. the investigators will conduct a historic population-based matched cohort study using danish nationwide registry data. eligible children are children 1.0-17.9 years diagnosed with acute lymphoblastic leukaemia (all) in denmark from 1994 till 2016. the primary outcome is yearly contact rates to primary healthcare.

acute lymphoblastic leukaemia (all) is the most frequent single form of cancer in children accounting for 40-45 new cases every year in denmark. over the past decades, advances in treatment have led to an increasing number of children who survive cancer and more than 80% of children with all now become long-term survivors. this means a growing population of childhood all survivors. in survivors, the cancer itself and treatment late-effects can lead to ongoing health care use. register studies of long-term survivors of childhood cancer have shown an increased risk of hospitalisation compared to the general population. it is mentioned in many of the studies that contact rates could be underestimated when looking at hospital contacts only. the literature about non-hospital-based contacts with a doctor in childhood cancer survivors is scarce.

Eligibility criteria:
inclusion criteria: * b-precursor all and t-all enrolled in the nopho all-92, all-2000 and all-2008 trials. * treated at one of the four danish paediatric oncology departments * age group 1.0-14.9 for the nopho all-92 and all-2000 trials. age group 1.0-17.9 for the nopho all-2008 trial. * completed maintenance therapy in the time period form 01.01.1997 till 31.12.2016 exclusion criteria: * children with down syndrome
to observe the efficacy and safety by comparing chemotherapy(docetaxel, oxaliplatin plus s1 ) followed with radical resection versus chemotherapy alone in advanced gastric cancer with single non-curable factor.

Conditions: Gastric Cancer

Summary: investigators assessed the effectiveness of conversional gastrectomy compared with chemotherapy alone following docetaxel, oxalipaltin and s1 therapy for advanced gastric cancer with a single non-curable factor.

palliative chemotherapy is still the standard of care for incurable advanced gastric cancer. several retrospective, single institutional studies have shown that the addition of gastrectomy to chemotherapy might improve patient survival among patients with metastatic gastric cancer with a single non-curable factor. however, regatta trial, a phase 3, randomized controlled trial, concluded an opposite conclusion that gastrectomy followed by chemotherapy did not show any survival benefit compared with chemotherapy alone in advanced gastric cancer with a single non-curable factor. interestingly, five patients initially assigned to chemotherapy alone in the study had got survival benefit form gastrectomy with curative intent because of complete disappear of all non-curable factors during chemotherapy. this finding raised the question as to conversional radical surgery following upfront chemotherapy could be a possible treatment option. we assessed the effectiveness of conversional radical surgery following docetaxel, oxalipaltin and s1 therapy for advanced gastric cancer with a single non-curable factor.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of gastric cancer with a single non-curable factor * a single non-curable factor was defined as hepatic metastasis (h1; two to four lesions of maximum diameter ≤5 cm and minimum diameter ≥1 cm); peritoneal metastasis (p1) in the diaphragm or peritoneum caudal to the transverse colon without massive ascites or intestinal obstruction; positive cytology (cy1) when the cancer cells were found in the peritoneal washing; para-aortic lymph node (pan) metastasis above the coeliac axis or below the inferior mesenteric artery (lymph node 16a1/b2 of maximum diameter ≥1 cm), or both; or ovary implant metastasis for one site or two. exclusion criteria: * patients who can have radical resection. * patietns who have more than one metastasis.
ciprofol sedation in patients undergoing liver cancer percutaneous radiofrequency ablation

Conditions: Liver Cancer; Ciprofol

Summary: efficacy and safety of ciprofol sedation in patients undergoing liver cancer percutaneous radiofrequency ablation

ciprofol was injected before ablation and sedation scores were measured to make sure certain sedation.

Eligibility criteria:
inclusion criteria: * patients who intend to undergoing ultrasound-guided percutaneous radiofrequency ablation of liver tumors; * age: 18-75 years old; * asa grade i-iii; * laboratory examination meets the following conditions: neutrophils \>1.5×109/l, platelet \>80×109/l, hemoglobin \>90g/l, aspartate transferase \<1.5×uln, total bilirubin \<1.5×uln, serum creatinine \<1.2 x uln; * chemotherapy \< 4 times. exclusion criteria: * patients who are known to be allergic to propofol, opioids, eggs, soy products, or patients who are contraindicated with these drugs or foods due to illness; * serious organ dysfunction and other systemic diseases, such as liver dysfunction, renal dysfunction; worsening congestive heart failure within the last 6 months resulting in hospitalization or adjustment of medication; severe aortic or mitral stenosis; heart surgery (heart valve replacement) within the last 6 months; acute myocardial infarction in the last 6 months; hemodynamic disturbance due to arrhythmia; respiratory diseases; cerebrovascular diseases; . taking propofol, opioids or other analgesic and sedative drugs 72 hours before . emergency surgery; * those who are unable to communicate with the researcher normally or who are deemed unsuitable by the researcher and refuse to participate in the study.

Keywords: radiofreqency ablation liver cancer ciprofol